)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
Jiangsu Jibeier Pharmaceutical
Jiangsu Jibeier Pharmaceutical (688566) investor relations material
Jiangsu Jibeier Pharmaceutical Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary28 Apr, 2026
Executive summary
Achieved revenue of ¥966.07 million, up 7.76% year-over-year; net profit attributable to shareholders was ¥261.61 million, up 19.28% year-over-year.
Gross margin remained high at 89.46%; core product Leucogen Tablets maintained market leadership.
R&D investment totaled ¥67.07 million, 6.94% of revenue; several innovative drugs advanced in clinical trials.
Cash dividend of ¥2.60 per 10 shares proposed, totaling ¥51.85 million, with a payout ratio of 19.82%.
No major quality or safety incidents; continued ESG and governance improvements.
Financial highlights
Operating income: ¥966.07 million, up 7.76% year-over-year.
Net profit attributable to shareholders: ¥261.61 million, up 19.28% year-over-year.
Operating cash flow: ¥248.30 million, up 15.33% year-over-year.
Basic and diluted EPS: ¥1.31, up 15.93% year-over-year.
Gross margin: 89.46%; net margin: 27.09%.
Outlook and guidance
Focus on expanding sales of Leucogen Tablets in oncology and Nitrendipine and Atenolol Tablets in cardiovascular segments.
Accelerate NDA submission for antidepressant JJH201501 and advance clinical trials for oncology drug JJH201601.
Continue investment in R&D and capacity expansion, with new production base and high-end formulation center under construction.
Maintain high dividend payout and stable financial policy.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jiangsu Jibeier Pharmaceutical
- Revenue up 12.2% but net profit and cash flow declined sharply year-over-year.688566
Q1 202628 Apr 2026 - Revenue and profit grew modestly, with strong R&D and asset expansion.688566Q4 202415 Dec 2025
- Net profit surged 22.4% on steady revenue growth and R&D advances.688566Q2 202512 Dec 2025
- Revenue up 3.9%, net profit down 5.7%, and R&D spending jumped 64% in Q1 2025.688566Q1 202512 Dec 2025
- Nine-month net profit rose 12.80% year-over-year, while Q3 profit declined 9.45%.688566Q3 202531 Oct 2025
- Q3 revenue up, but net profit declined on higher R&D; YTD profit and cash flow improved.688566Q3 202413 Jun 2025
- Net profit rose 26.74% on steady revenue and robust R&D, with pipeline and financing progress.688566Q2 202413 Jun 2025
Next Jiangsu Jibeier Pharmaceutical earnings date
Q2 202628 Aug, 2026
Jiangsu Jibeier Pharmaceutical
Next Jiangsu Jibeier Pharmaceutical earnings date
Q2 202628 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage